检索结果-南通市图书馆

电针对心肌肥厚小鼠心肌组织瞬时受体电位通道的影响

在线全文

学校读者我要写书评

暂无评论

针刺研究 2024年第6期49卷 558-565页

作者：谢玉华邢馨玉钟文吴生兵周美启崔帅安徽中医药大学研究生院合肥230012 经脉脏腑相关安徽省重点实验室合肥230038 安徽中医药大学针灸推拿学院合肥230012

目的:观察电针“内关”对心肌肥厚小鼠心功能、心脏形态和心肌组织中瞬时受体电位通道(TRPCs)蛋白表达的影响,探讨电针治疗心肌肥厚的作用机制。方法:C57BL/6小鼠随机分为空白组、模型组和电针组,每组15只。皮下注射盐酸异丙肾上腺素(15... 详细信息

目的:观察电针“内关”对心肌肥厚小鼠心功能、心脏形态和心肌组织中瞬时受体电位通道(TRPCs)蛋白表达的影响,探讨电针治疗心肌肥厚的作用机制。方法:C57BL/6小鼠随机分为空白组、模型组和电针组,每组15只。皮下注射盐酸异丙肾上腺素(15 mg·kg^(-1)·d^(-1))制备心肌肥厚模型。电针组电针双侧“内关”,每次20 min,每日1次,连续14 d。测量小鼠体质量、胫骨长度和心脏质量;超声心动图测量小鼠心室射血分数(EF)、短轴缩短指数(FS)、收缩末期左心室容积(LVEV)、收缩末期左心室内径(LVID)和收缩末期左心室后壁厚度(LVPW)以评价心功能;WGA染色法检测小鼠心肌相对细胞个数和相对细胞平均表面积;HE染色法观察心肌细胞形态变化;qPCR及Western blot法检测心肌组织中TRPC1、TRPC3、TRPC4、TRPC6的mRNA和蛋白表达水平。结果:与空白组比较,模型组小鼠心体比和心胫比均增加(P<0.05,P<0.01),EF、FS、LVPW降低(P<0.01),LVEV、LVID升高(P<0.01),心肌相对细胞个数减少(P<0.05),心肌相对细胞表面积增加(P<0.01),左心室面积比值升高(P<0.05),左心室后壁比值降低(P<0.05),心肌细胞排列紊乱,心肌间质炎性细胞浸润明显,心肌组织TRPC1、TRPC3、TRPC4、TRPC6 mRNA和蛋白表达明显升高(P<0.01)。与模型组相比,电针组小鼠心体比和心胫比均减小(P<0.01),EF、FS、LVPW升高(P<0.01),LVEV、LVID降低(P<0.01),心肌相对细胞个数增加(P<0.05),相对细胞表面积减小(P<0.05),左心室面积比值降低(P<0.05),左心室后壁比值升高(P<0.05),心肌病理损伤程度减轻,心肌组织TRPC1、TRPC3、TRPC4、TRPC6 mRNA和蛋白表达降低(P<0.01,P<0.05)。结论:电针“内关”能够改善心肌肥厚小鼠的心脏形态和功能,其机制可能与下调TRPCs有关。

关键词：心肌肥厚电针瞬时受体电位通道心脏功能

GFRP筋混杂纤维混凝土隧道管片力学性能研究

在线全文

学校读者我要写书评

暂无评论

工程力学 2024年第S1期41卷 238-244,252页

作者：陈晟晟周春恒章子华宁波大学土木工程与地理环境学院宁波315211

为研究GFRP筋混杂纤维混凝土隧道管片的力学性能,进行了三个不同GFRP筋配筋率的钢-聚丙烯纤维混凝土管片静力受弯试验,获得了试件的破坏形态、承载力及裂缝扩展模式。考虑GFRP筋与混杂纤维混凝土的界面黏结,采用ABAQUS建立了GFRP筋混杂... 详细信息

为研究GFRP筋混杂纤维混凝土隧道管片的力学性能,进行了三个不同GFRP筋配筋率的钢-聚丙烯纤维混凝土管片静力受弯试验,获得了试件的破坏形态、承载力及裂缝扩展模式。考虑GFRP筋与混杂纤维混凝土的界面黏结,采用ABAQUS建立了GFRP筋混杂纤维混凝土管片的有限元模型,分析了不同混杂纤维掺量和配筋率对管片受弯承载力的影响。研究结果表明:GFRP筋混杂纤维混凝土管片的破坏主要是由跨中主裂缝贯穿和GFRP筋材断裂导致;在纤维体积掺量不变的情况下,提高纵向受拉GFRP筋的配筋率,可以有效提高管片的受弯承载力;在数值计算中,考虑GFRP筋与混杂纤维混凝土的界面黏结滑移的有限元模型能更准确地模拟试件的开裂荷载、极限荷载和弯曲刚度;在承载力不变的情况下,增加混杂纤维的体积分数能有效减少管片的配筋率,并且提高管片的抗变形能力;通过回归分析,提出了纤维掺量与配筋率关系的计算式,理论计算结果与数值结果符合较好。

关键词： GFRP筋混杂纤维混凝土配筋率静力受弯试验界面黏结有限元模型

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2024年第1期44卷 127-172页

作者： Feng-hua Wang Xiao-Tian Zhang Lei Tang Qi Wu Mu-Yan Cai Yuan-Fang Li Xiu-Juan Qu Hong Qiu Yu-Jing Zhang Jie-Er Ying Jun Zhang Ling-Yu Sun Rong-Bo Lin Chang Wang Hao Liu Miao-Zhen Qiu Wen-Long Guan sheng-Xiang Rao Jia-Fu Ji Yan Xin Wei-Qi sheng Hui-Mian Xu Zhi-Wei Zhou Ai-Ping Zhou Jing Jin Xiang-Lin Yuan Feng Bi Tian-Shu Liu Han Liang Yan-Qiao Zhang Guo-Xin Li Jun Liang Bao-Rui Liu Lin Shen Jin Li Rui-hua Xu Department of Medical Oncology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer HospitalBeijingP.R.China Department of Radiology Peking University Cancer HospitalBeijingP.R.China Department of Endoscopy Center Peking University Cancer HospitalBeijingP.R.China Department of Pathology Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineGuangzhouGuangdongP.R.China Department of Gastric Surgery Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Medical Oncology The First Hospital of China Medical UniversityShenyangLiaoningP.R.China Department of Medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubeiP.R.China Department of Radiotherapy Sun Yat-sen University Cancer CenterState Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineGuangzhouGuangdongP.R.China Department of Medical Oncology Zhejiang Cancer HospitalHangzhouZhejiangP.R.China Department of Medical Oncology Ruijin HospitalShanghai Jiaotong University School of MedicineShanghaiP.R.China Department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiangP.R.China Department of Medical Oncology Fujian Cancer HospitalFuzhouFujianP.R.China Tumor Center The First Hospital of Jilin UniversityChangchunJilinP.R.China Department of General Surgery Nanfang HospitalSouthern Medical UniversityGuangzhouGuangdongP.R.China Department of Radiology Zhongshan HospitalFudan UniversityShanghaiP.R.China Department of

The 2023 update of the Chinese Society of Clinical Oncology(CSCO)Clini-cal Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China,reflecting the latest advancements in evidence-based medicine,healthcare resource availability,and precision medicine.These updates address the differences in epidemiological characteristics,clinicopatho-logical features,tumor biology,treatment patterns,and drug selections between Eastern and Western gastric cancer patients.Key revisions include a structured template for imaging diagnosis reports,updated standards for molecular marker testing in pathological diagnosis,and an elevated recommendation for neoadju-vant chemotherapy in stage III gastric cancer.For advanced metastatic gastric cancer,the guidelines introduce new recommendations for immunotherapy,anti-angiogenic therapy and targeted drugs,along with updated management strategies for human epidermal growth factor receptor 2(HER2)-positive and deficient DNA mismatch repair(dMMR)/microsatellite instability-high(MSI-H)patients.Additionally,the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric cancer.The 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice,particularly in the heterogeneous healthcare landscape of China,while maintaining a commitment to scientific rigor,impartiality,and timely revisions.

关键词： Chinese Society of Clinical Oncology(CSCO) gastric cancer diagnosis surgery neoadjuvant adjuvant radiotherapy chemotherapy targeted therapy immunotherapy

B meson rare decays in the TNMSSM

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese Physics C 2024年第5期48卷 72-91页

作者：陈海翔高生恺朱宁宇张兆阳胡怀聪 School of Physical Science and Technology Guangxi UniversityNanning 530004China

We investigate the two loop electroweak corrections to B meson rare decays B¯→Xsγand B0s→μ+μ−in the minimal supersymmetry standard model(MSSM)extension with two triplets and one singlet(TNMSSM).The new particle contents and interactions in the TNMSSM can affect the theoretical predictions of the branching ratios Br(B¯→Xsγ)and Br(B0s→μ+μ−),and the corrections from two loop diagrams to the process B¯→Xsγcan reach around 4%.Considering the latest experimental measurements,the numerical results of Br(B¯→Xsγ)and Br(B0s→μ+μ−)in the TNMSSM are presented and analyzed.The findings indicate that the results in the TNMSSM can fit the updated experimental data well,and the new parameters Tλ,κ,λ,clearly affect the theoretical predictions of Br(B¯→Xsγ)and Br(B0s→μ+μ−).

关键词： supersymmetry B physics rare decays

Intraperitoneal injection but not oral administration of ellagic acid: A novel immunomodulator via targeting casein kinase 2 signaling pathway

在线全文

学校读者我要写书评

暂无评论

Food Science and Human Wellness 2024年

作者： Wen-Hui Qi Bing Han Ting-Ting cui Pei-Xin Shen Zhuo-hua Zhao Ya-Ping Yan Li-Bin Wang Xin-Yu Lu Yuan Zhang Xing Li Key Laboratory of Medicinal Resources and Natural Pharmaceutical Chemistry (Shaanxi Normal University) The Ministry of Education College of Life Sciences Shaanxi Normal University Department of Pharmacology School of Pharmacy Fourth Military Medical University The Nervous System Disease Diagnosis and Treatment Engineering Technology Research Center of Ningxia School of Medical Technology Xi'an Medical University

Immunosuppressants currently approved for the treatment of autoimmune diseases and organ transplant rejection present diverse adverse effects that impair the life quality of patients. Therefore， the development of novel immunomodulators with high efficiency and low toxicity is essential. Ellagic acid (EA)， a natural polyphenol compound widely distributed in berries， is metabolically transformed by gut microbiome to exert systemic health benefits. Here， we identified that intraperitoneal administration of EA with no cytotoxicity， beyond its well-known oral metabolic fate， effectively decreased clinical severity and CNS inflammation/demyelination in experimental autoimmune encephalomyelitis (EAE)， a mouse model of an autoimmune disease multiple sclerosis (MS). Interestingly， intraperitoneal EA administration at incredibly low doses (0.1 mg/kg/d) is dose-sparing with fingolimod (FTY720)， the first FDA-approved oral drug for MS. In addition， intraperitoneal EA also ameliorated the brain damage in a neuromyelitis optica (NMO) model， and significantly prevented the immune rejection of allograft skin graft. Evidence from pharmacological studies combined with RNA-seq indicate that prototype EA functions by a mechanism that involves direct inhibition of casein kinase II (CKII) to suppress the expression of IL-17 and promote the expression of Cpt1a to regulate Th17 differentiation. In conclusion， our study demonstrates that the prototype EA entering the blood circulation acts as a novel therapeutic immunomodulator for the treatment of autoimmune diseases and transplant rejection through the CKⅡ-mediated JAK/STAT/Cpt1a signaling pathway.

关键词：

锶同位素溯源植物遗存产区的研究进展及对清宫道地药材溯源的启示

在线全文

同方期刊数据库

学校读者我要写书评

暂无评论

中国中药杂志 2024年第1期49卷 39-45页

作者：姜云璐彭华胜杨滨中国中医科学院中药资源中心道地药材品质保障与资源持续利用全国重点实验室北京100700 中医药文物研究国家文物局重点科研基地(中国中医科学院中药研究所) 北京100700 中国中医科学院中药研究所北京100700

锶同位素(87Sr/86Sr)溯源技术目前已广泛应用于动物遗存与现代食品产地溯源研究,但由于样品的污染与清洗问题,仅有较少的植物遗存溯源工作中应用此技术。故宫博物院保存有1000余件清宫药材文物,是研究道地药材不可多得的珍贵材料。清宫... 详细信息

锶同位素(87Sr/86Sr)溯源技术目前已广泛应用于动物遗存与现代食品产地溯源研究,但由于样品的污染与清洗问题,仅有较少的植物遗存溯源工作中应用此技术。故宫博物院保存有1000余件清宫药材文物,是研究道地药材不可多得的珍贵材料。清宫药材得益于良好的保存环境,能够避免外源锶污染的问题,因此能够在其溯源研究中引入锶同位素技术。在此基础上,该文将论述锶同位素溯源技术的原理,并总结了目前锶同位素溯源植物遗存的研究进展。此外,该文讨论了锶同位素应用于清宫药材溯源研究时遇到的锶同位素比值地图的绘制、溯源结果区域范围大、样品的污染与清洗3个关键性问题及相应解决办法。清代文献史料是了解清代道地药材的分布与应用的重要依据,在文献研究基础上,锶同位素溯源清宫药材产区为相关研究提供了实物证据。文献史料与药材文物二重证据共同溯源清宫药材的来源产区,将为清代道地药材研究提供新的视角,同时也为道地药材产区变迁研究提供参考。

关键词：锶同位素 87Sr/86Sr 本草考古道地药材产区溯源

在线全文

学校读者我要写书评

暂无评论

玄武岩纤维棒聚合物混凝土的弯曲韧性

建筑材料学报 2024年第2期27卷 99-105页

作者：崔圣爱徐李麟饶家锐曹卓颖西南交通大学土木工程学院四川成都610031

研究了玄武岩纤维棒(BFB)的纤维增强指数I_(R)对玄武岩纤维棒聚合物混凝土(BFB-PC)韧性指标T_((2(n-1)))(n)的影响,通过分形理论探究了T_((2(n-1)))(n)与裂缝形貌的关系,并建立了弯曲韧性计算模型.结果表明:当IR=90.0时,BFB对BFB-PC的... 详细信息

研究了玄武岩纤维棒(BFB)的纤维增强指数I_(R)对玄武岩纤维棒聚合物混凝土(BFB-PC)韧性指标T_((2(n-1)))(n)的影响,通过分形理论探究了T_((2(n-1)))(n)与裂缝形貌的关系,并建立了弯曲韧性计算模型.结果表明:当IR=90.0时,BFB对BFB-PC的增韧效果最优,此时BFB-PC的弯曲韧性比未掺BFB时提升了8.39倍;BFB的增韧阈值为IR=37.5和IR=90.0;当IR相同时,与未掺聚合物的混凝土相比,聚灰比为0.06的BFB-PC T_((2(n-1)))(n)更高;IR越大裂缝形貌越复杂,T(2(n-1))(n)与裂缝分形维数呈二次函数关系;本文提出的弯曲韧性计算模型准确描述了BFB对PC梁的增韧作用,其试验值与理论值的相对误差小于15.00%.

关键词：聚合物混凝土玄武岩纤维棒纤维增强指数韧性指标分形维数

Chinese herbal medicine decreases incidence of hepatocellular carcinoma in diabetes mellitus patients with regular insulin management

在线全文

学校读者我要写书评

暂无评论

World Journal of Gastrointestinal Oncology 2024年第3期16卷 716-731页

作者： Hsiang-Chun Lai Ju-Chien Cheng Hei-Tung Yip Long-Bin Jeng sheng-Teng huang Graduate Institute of Chinese Medicine School of Chinese MedicineCollege of Chinese MedicineChina Medical UniversityTaichung 404328TaiwanChina Department of Medical Laboratory Science and Biotechnology China Medical UniversityTaichung 404TaiwanChina Management Office for Health Data China Medical University HospitalTaichung 404327TaiwanChina Organ Transplantation Center China Medical University HospitalTaichung 40447TaiwanChina Department of Chinese Medicine China Medical University HospitalSchool of Chinese MedicineChina Medical UniversityTaichung 40447TaiwanChina

BACKGROUND Type 2 diabetes mellitus(DM)is an independent risk factor for hepatocellular carcinoma(HCC),while insulin is a potent mitogen.Identifying a new therapeutic modality for preventing insulin users from developing HCC is a critical goal for researchers.AIM To investigate whether regular herbal medicine use can decrease HCC risk in DM patients with regular insulin control.METHODS We used data acquired from the Taiwan,Chinaese National Health Insurance research database between 2000 and 2017.We identified patients with DM who were prescribed insulin for>3 months.The herb user group was further defined as patients prescribed herbal medication for DM for>3 months per annum during RESULTS We initially enrolled 657144 DM patients with regular insulin use from 2000 to 2017.Among these,46849 patients had used a herbal treatment for DM,and 140547 patients were included as the matched control group.The baseline variables were similar between the herb users and nonusers.DM patients with regular herb use had a 12%decreased risk of HCC compared with the control group[adjusted hazard ratio(aHR)=0.88,95%CI=0.80–0.97].The cumulative incidence of HCC in the herb users was significantly lower than that of the nonusers.Patients with a herb use of>5 years cumulatively exhibited a protective effect against development of HCC(aHR=0.82,Phuang Qi)plus Salvia miltiorrhiza Bunge(Dan Shen),and Astragalus propinquus(huang Qi)plus Trichosanthes kirilowii Maxim.(Tian hua Fen)were the most frequent combination of single herbs.Meanwhile,Ji sheng Shen Qi Wan plus Dan Shen was the most frequent combination of herbs and formulas.CONCLUSION This large-scale retrospective cohort study reveals that herbal medicine may decrease HCC risk by 12%i

关键词： Hepatocellular carcinoma Diabetes mellitus Insulin Herb Taiwan,Chinaese National health insurance research database

全国统一大市场建设与共同富裕:基于地区市场分割视角

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

中国流通经济 2024年第7期38卷 61-75页

作者：周鹃盛宇华南京师范大学商学院江苏南京210023

共同富裕是社会主义的本质要求,是现阶段全党工作的重中之重。构建全国统一大市场是实现全体人民共同富裕的基础。而在我国渐进式改革的过程中催生的地区市场分割导致国内市场难以实现一体化,人群、城乡及地区间收入差距扩大,使共同富... 详细信息

共同富裕是社会主义的本质要求,是现阶段全党工作的重中之重。构建全国统一大市场是实现全体人民共同富裕的基础。而在我国渐进式改革的过程中催生的地区市场分割导致国内市场难以实现一体化,人群、城乡及地区间收入差距扩大,使共同富裕失去了物质基础。因此,从地区市场分割视角探究全国统一大市场建设的共同富裕效应具有重要意义。利用2006—2022年我国30个省份的面板数据,借助系统GMM方法和中介效应模型实证考察地区市场分割对共同富裕的影响效应及其地区异质性,并进一步分析其作用机制。研究发现:地区市场分割对共同富裕产生显著的负向效应,明显抑制我国共同富裕水平的提升,这一结论经过稳健性检验后仍然成立。从市场分割细分类型来看,商品市场分割、劳动力市场分割与资本市场分割均对共同富裕产生显著的抑制作用,其中劳动力市场分割的抑制作用最大,其次是商品市场分割,资本市场分割相对较小。地区异质性分析表明,相比东部和中部地区,西部地区市场分割对共同富裕的负向效应最大,且不同类型市场分割对共同富裕的影响也存在明显的地区异质性,其中东部地区共同富裕水平的提升主要受商品市场分割的制约;中部地区共同富裕水平的提升主要受劳动力市场和资本市场分割的制约;不同类型市场分割都不利于西部地区共同富裕水平的提升。机制检验结果表明,地区市场分割主要通过阻碍产业结构升级、加重要素价格扭曲、加剧环境污染和降低财政可持续,对共同富裕水平的提升产生抑制作用。基于此,加快推进全国统一大市场建设,打破商品市场、劳动力市场与资本市场分割,充分发挥市场机制配置要素资源的决定性作用,强化地区间分工与协作,推动区域协调发展,助力共同富裕的实现。

关键词：全国统一大市场共同富裕地区市场分割系统GMM 中介效应